Gossamer Bio adds Greg Ciongoli to board and audit committeeSep 16PeopleGossamer Bio, Inc.seralutinib
Gossamer Bio secures up to $250 million private placement tied to seralutinib milestonesAug 21Regulatory decisionGossamer Bio, Inc.seralutinib
Gossamer reports Q2 2026 results, reacquires seralutinib rights from ChiesiAug 13Quarterly updateGossamer Bio, Inc.seralutinib
Gossamer Bio reacquires worldwide seralutinib rights from Chiesi, targets September NDAJul 27PartnershipGossamer Bio, Inc.seralutinib
Sign inSign in